Blood Platelets in the Progression of Alzheimer’s Disease

Nina S. Gowert1, Lili Donner1, Madhumita Chatterjee2, Yvonne S. Eisele3,4, Seyda T. Towhid5, Patrick Münzer5, Britta Walker4, Isabella Ogorek6, Oliver Borst2,5, Maria Grandoch7, Martin Schaller8, Jens W. Fischer7, Meinrad Gawaz2, Sascha Weggen6, Florian Lang5, Mathias Jucker3, Margitta Elvers1,2*

1 Department of Clinical and Experimental Hemostasis, Hemotherapy and Transfusion Medicine, Heinrich-Heine-University, Düsseldorf, Germany, 2 Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Eberhard-Karls-Universität, Tübingen, Germany, 3 Department of Cellular Neurology, Hertie-Institut für Klinische Brain Research, Eberhard-Karls University, Tübingen, Germany, 4 DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany, 5 Department of Physiology, Eberhard-Karls University, Tübingen, Germany, 6 Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany, 7 Institut für Pharmakologie u. Klinische Pharmakologie, Universitätsklinikum der Heinrich-Heine-Universität, Düsseldorf, Germany, 8 Department of Dermatology, Eberhard-Karls University, Tübingen, Germany

Abstract

Alzheimer’s disease (AD) is characterized by neurototoxic amyloid-ß plaque formation in brain parenchyma and cerebral blood vessels known as cerebral amyloid angiopathy (CAA). Besides CAA, AD is strongly related to vascular diseases such as stroke and atherosclerosis. Cerebrovascular dysfunction occurs in AD patients leading to alterations in blood flow that might play an important role in AD pathology with neuronal loss and memory deficits. Platelets are the major players in hemostasis and thrombosis, but are also involved in neuroinflammatory diseases like AD. For many years, platelets were accepted as peripheral model to study the pathophysiology of AD because platelets display the enzymatic activities to generate amyloid-ß (Aß) peptides. In addition, platelets are considered to be a biomarker for early diagnosis of AD. Effects of Aß peptides on platelets and the impact of platelets in the progression of AD remained, however, ill-defined. The present study explored the cellular mechanisms triggered by Aß in platelets. Treatment of platelets with Aß led to platelet activation and enhanced generation of reactive oxygen species (ROS) and membrane scrambling, suggesting enhanced platelet apoptosis. More important, platelets modulate soluble Aß into fibrillar structures that were absorbed by apoptotic but not vital platelets. This together with enhanced platelet adhesion under flow ex vivo and in vivo and platelet accumulation at amyloid deposits of cerebral vessels of AD transgenic mice suggested that platelets are major contributors of CAA inducing platelet thrombus formation at vascular amyloid plaques leading to vessel occlusion critical for cerebrovascular events like stroke.

Introduction

Deposits of Aß are the characteristic pathological hallmarks of Alzheimer’s disease (AD), an age-related neurodegenerative disorder and the most common form of senile dementia [1]. Recent studies provided strong evidence that misfolding and aggregation of Aß is a crucial event in the pathogenesis of AD [1], followed by neuron loss and declined cognitive and memory capability, affecting about 26 million people worldwide with tendency to rise [2]. In recent years, AD has been recognized to be a more intriguing disorder affecting other peripheral tissues beside the brain demonstrating that alterations in AD patients occur not only in the central nervous system but also in blood vessels and blood cells leading to amyloid-ß deposits in cerebral vessels known as cerebral amyloid angiopathy (CAA) [3]. CAA plays an important role in the severity of AD pathology because it induces degeneration or even destruction of the vessel wall and affects cerebral blood flow [3]. Besides CAA, recent studies provide strong evidence that AD is strongly related to the vascular system. Different clinical trials provide evidence that AD is related to vascular diseases such as stroke [4], atherosclerosis [2] and hypertension [5]. These vascular risk factors increase the risk for AD [6], and moreover, cerebrovascular dysfunction occurs in AD patients leading to alterations in blood flow that might play an important role in AD pathology with neuronal loss and memory deficits [7,8]. To date the mechanisms how Aß could alter thrombosis and hemostasis is not known but it is hypothesized that Aß might be involved in blood flow and blood vessel function [9,10].

Platelets are anucleus cells crucial for hemostasis at sites of vascular injury. However, uncontrolled platelet activation can lead to acute vessel occlusion leading to myocardial infarction and stroke [11]. In the last years it has become increasingly evident that platelets are also important players in inflammation, angiogenesis and tumor progression [11]. Furthermore, platelets express the amyloid precursor protein (APP) and display the complete enzymatic machinery to process APP proteins into amyloid-ß (Aß) peptides through a pathway known in the brain [2]. Thus platelets have been considered to be a good model to study neurodegenerative diseases like AD for decades.
In the last years, platelets were used to study metabolic mechanisms relevant in the central nervous system and related to AD. Signalling pathways in platelets leading to platelet activation and aggregation have been described to also modulate APP processing [12,13]. Platelets contain high levels of APP with different expression pattern compared to the brain [14] but represent the fundamental repository of Aβ in blood that might contribute to the accumulation of Aβ in brain and its vasculature [15–17]. So far, the physiological role of platelet APP and its metabolites is, however, ill-defined. Different studies propose that APP may act as a receptor on the platelet surface [18] and might be involved in Ca²⁺ mobilization [19].

Platelets can release Aβ and become activated by synthetic Aβ peptides [20]. The processing of APP in platelets of AD patients is altered compared to control subjects suggesting since several years that platelets may be a biomarker for the diagnosis of AD. For instance, Rosenberg and co-workers showed altered APP processing in platelets of AD patients and found platelet APP isoforms to correlate with declining cognition in AD [21,22].

Platelets are major players in vascular diseases associated with AD such as atherosclerosis and stroke [11]. In addition, blood flow alterations induced by CAA or AD-related vascular diseases with consecutively hypoperfusion induced by vessel occlusion point to a second effect of Aβ in brain beside its neurotoxic effects [3]. This suggests that platelets not only mirror AD related events in the brain but might influence the progression of AD. Although much effort has been made to understand the role of platelets in AD, the molecular mechanisms involved and the impact of platelets in AD is not well understood.

The present study explored the mechanisms underlying the effects of amyloid-β on platelets. It is shown that amyloid-β exposure leads to platelet activation, Aβ release, ROS generation and membrane scrambling. Furthermore, we provided strong evidence that platelets contribute to CAA by modulation of soluble into fibrillar Aβ and facilitation of platelet adhesion and accumulation at vascular amyloid-β deposits leading to full occlusion of affected cerebral vessels critical for ischemic cerebrovascular events like stroke.

Results

Contact of Platelets with Synthetic Aβ Leads to Platelet Aβ Production

Recent studies provide evidence that platelets are able to process and release Aβ peptides, processes enhanced by platelet stimulation with the platelet agonist thrombin [23]. To investigate Aβ production of platelets in further detail, we isolated human and murine platelets, respectively and cultured platelets for 1–10 days with a synthetic soluble 40-residue Aβ peptide to test whether platelets are affected by contact with soluble Aβ found in blood by clearance of the CSF-brain system in normal individuals [24,25]. Surprisingly, we found Aβ(1–42) in platelet lysates after contact of platelets with soluble synthetic Aβ that emerged to be concentration-dependent (Fig. 1A). While 50 ng/ml of soluble Aβ does not influence the amount of Aβ (1–42) in platelet cell lysates as measured by ELISA (10.8±1.77 pg/ml versus 12.05±0.28 pg/ml, day 1, Fig. 1A, left panel), incubation of platelets with high doses of Aβ peptide (50 μg/ml) led to a strong increase of Aβ (1–42) in platelet lysates (15.2±4.12 pg/ml versus 300.3±41.22 pg/ml, day 1; Fig. 1A, right panel). However, these results do not disclose if we measured Aβ sticking to the platelet cell surface or if detected Aβ is located to the cytoplasm or granules of platelets.

Consequently, we analyzed the release of Aβ (1–42) from Aβ-stimulated platelets and found a moderate increase in Aβ levels when platelets were stimulated with low doses of Aβ (50 ng/ml) (1.1±0.22 pg/ml versus 100.4±1.67 pg/ml, day 1; 0.4±0.21 pg/ml versus 112.9±21.33 pg/ml, day 3; 0.5±0.01 pg/ml versus 155.7±17.8 pg/ml, day 7; 0.1±0.02 pg/ml versus 77.8±7.11 pg/ml, day 10; Fig. 1B, left panel) while high doses of Aβ peptide (50 μg/ml) induced a strong increase in Aβ (1–42) release into the supernatant of platelets (24.1±6.02 pg/ml versus 1229.8±9.14 pg/ml, day 1; 24.4±6.03 pg/ml versus 1939.9±200.81 pg/ml, day 3; 26.9±2.0 pg/ml versus 2081.9±215.03 pg/ml, day 7; 23.2±7.36 pg/ml versus 1892.5±195.44 pg/ml, day 10; Fig. 1B, right panel). Thus, we conclude that contact of platelets with soluble synthetic Aβ peptides is able to stimulate Aβ (1–42) accumulation in/on platelets and also the release of Aβ (1–42) from platelets in a time- and concentration-dependent manner. Control experiments (Fig. S1) showed that the Aβ (1–42) ELISA we used is not entirely specific for Aβ42. Therefore all results of Fig. 1A–B were corrected according to the respective controls (181.25±19.276 pg/ml in cultures with 50 μg/ml Aβ; 1.345±0.076 pg/ml in cultures with 50 ng/ml Aβ) to consider crossreactivity of Aβ40 and Aβ42.

In further experiments we treated platelets with the γ-secretase inhibitor LY 411575. Surprisingly, we found only less differences when we compared platelets that were treated with LY 411575 and untreated platelets (Fig. 1C) suggesting that most of the Aβ42 measured by ELISA was not produced by platelets but is a result from platelet-mediated modification of Aβ40 that was added to the platelet cell culture.

In addition, we activated platelets with Aβ peptide and stained the cells using an Aβ antibody (6E10) and found platelets to be positive for Aβ within the whole culture period of 1 to 10 days (Fig. 1D).

To investigate the distribution of APP and Aβ in platelets, we performed immunoelectron microscopy and found that APP was localized to platelet granule structures and at the plasma membrane of platelets. Aβ was only marginally detected at the plasma membrane but not inside the cell (Fig. 1E). Statistical analysis of all images obtained from this experiment proved low detection of Aβ (Fig. 1F).
Platelets become Activated by Stimulation with Low and High Doses of Aβ

To determine the impact of soluble Aβ on platelet activation we first performed electron microscopy and confirmed morphological changes of platelets after incubation with Aβ for 24 hrs. In contrast to the platelet suspension without stimulus, Aβ-treated platelets showed typical characteristics of activated platelets such as transport of granules to the plasma membrane, concentration of actin, roundish morphology and already granule free cytoplasm possibly due to release of their α- and dense granule content (Fig. 2A). In addition we observed platelet aggregates after Aβ stimulation (Fig. 2A).

Subsequent analysis of platelet degranulation (P-selectin expression) and β3-integrin activation (JON/A-binding) in response to Aβ stimulation by flow cytometry revealed that Aβ amplifies ADP-mediated platelet responses e.g. P-selectin expression (degranulation marker) and β3-integrin activation (Fig. 2B) but is not sufficient to induce degranulation and integrin activation without additional stimulus suggesting that prolonged exposure of platelets to Aβ might be required to induce full platelet activation without additional stimulus.

Determination of P-selectin expression in platelet cell culture with a singular treatment of soluble Aβ over a time period of 10 days confirmed the results obtained from electron microscopy (Fig. 2C). We found P-selectin positive platelets over the whole time period with peak values at day 3 and 7 (Fig. 2C). Fluorescent annexin V was utilized to identify phosphatidylserine exposing platelets as indicator for coagulant activity of platelets [26]. As illustrated in Fig. 2D, exposure to Aβ resulted in annexin V binding to the surface of platelets. The effect of Aβ on annexin V binding reached statistical significance at ≥20 ng/ml Aβ concentration. In addition, stimulation of platelets with Aβ induced the formation of microparticles comparable to the extent of thrombin stimulation. Fig. 2E shows a significant increase in microparticle release after Aβ stimulation (>5 ng/ml).

Aβ Stimulation Induces Platelet ROS Generation and Cell Membrane Scrambling

Reactive oxygen species (ROS) are chemically reactive molecules with important cell function in signaling and homeostasis [27]. ROS levels can increase upon environmental stress to control cellular function including apoptosis [28]. To investigate the impact of Aβ in ROS generation of platelets we performed experiments using flow cytometry and found increasing ROS levels when platelets were stimulated with Aβ (Fig. 3A). To promote removal of aged or activated platelets from the circulation, platelet senescence is associated with changes characteristic of apoptosis [29]. Caspases are central molecules of cell apoptosis and different studies showed that caspases also play a role in platelet activation and senescence [29–31].

Thus in additional experiments caspase-3 activity was analyzed by flow cytometry using platelets stimulated with increasing concentrations of Aβ. As apparent from Fig. 3B exposure to Aβ increased caspase-3 activity, an effect reaching statistical significance at ≥10 ng/ml Aβ concentration. Furthermore, cell culture experiments showed caspase-3 positive platelets upon Aβ...
stimulation over a time period of 10 days with peak values at day 10 (Fig. 3C).

Another hallmark of apoptosis is cell shrinkage. Thus cell volume was estimated from forward scatter in flow cytometry. As illustrated in Fig. 3D, Aβ exposure was followed by a decrease of forward scatter reflecting cell shrinkage. Additional experiments aimed to identify mechanisms possibly involved in the stimulation of cell membrane scrambling by Aβ. In a first series of experiments, cytosolic Ca²⁺ activity was estimated utilizing Fluoro-3AM fluorescence. As illustrated in Fig. 3E, exposure of platelets to Aβ increased Fluoro-3AM fluorescence, an effect reaching statistical significance at 20 ng/ml Aβ concentration. In further experiments mitochondrial cell membrane potential was determined utilizing DiOC₆ fluorescence. As shown in Fig. 3F, exposure to Aβ was follow by a decline of the mitochondrial potential, an effect reaching statistical significance at ≥10 ng/ml Aβ concentration.

Additional experiments explored whether the observed alterations of cytosolic Ca²⁺ and of caspase-3 activity, contributed to or even accounted for the stimulation of cell membrane scrambling following Aβ exposure. The impact of Ca²⁺ entry was explored by exposing platelets in the presence and absence of extracellular Ca²⁺ (addition of Ca²⁺ chelator EGTA instead of Ca²⁺). In a separate series of experiments platelets were pre-treated with pan-caspase inhibitor zVAD-FMK [1 μM] prior to Aβ exposure. As shown in Fig. 3G (left panel), pre-treatment with the extra-cellular Ca²⁺ chelator EGTA or pan-caspase-3 inhibitor zVAD significantly blunted cell membrane scrambling by Aβ treatment. Additional experiments elucidated the effect of Ca²⁺ removal on Aβ-induced caspase-3 activation. As illustrated in Fig. 3G (right panel), the effect of Aβ on caspase-3 activity was significantly blunted in the absence of Ca²⁺.

Amyloid-β Deposits in Platelet Cell Culture: Modulation of Soluble Aβ Peptides by Platelets

To further investigate, whether platelets are able to modify Aβ peptides, we cultured platelets with soluble, synthetic Aβ and analyzed modulation of Aβ into amyloid fibrils by Congo red staining. Interestingly, we found Congo red-positive Aβ deposits in platelet cell culture that were determined at different time points to analyze Aβ aggregate formation by differential interference contrast (DIC) microscopy. As shown in Fig. 4A, platelets were congo red-positive after incubation with soluble synthetic Aβ (50 μg/ml) for 3 days (early state). In addition, small extracellular fibrillar Aβ aggregates were also detected.

When platelets were stimulated with soluble Aβ for a longer time period (10 days, late state), large extracellular Aβ deposits that were Congo red-positive were determined by DIC microscopy suggesting, that either platelets were able to produce a great amount of Aβ fibrils or that they have the ability to modulate soluble synthetic Aβ (Fig. 4B). To test this hypothesis, we incubated platelets with synthetic Aβ and the the γ-secretase inhibitor LY-411575 to avoid Aβ production by platelets. Treatment of platelets with the γ-secretase inhibitor led again to congo red-positive Aβ deposits comparable to those without inhibitor treatment (Fig. 4C). Thus, platelets are apparently able to modulate the soluble, synthetic Aβ into fibrillar Aβ that are deposited in platelet cell culture in a time- and concentration-dependent manner (Fig. 4 and Fig. S3). Using murine platelet cell culture we were able to confirm that also murine platelets are able to modulate soluble Aβ peptides (Fig. S2).

Incorporation of Extracellular, Synthetic Aβ by Platelets Depends on Platelet Vitality

To analyze platelet mediated modulation of Aβ in further detail, we tested, whether platelets are able to absorb Aβ as observed for macrophages [32]. Thus, we incubated platelets with pre-aggregated FAM-labeled Aβ for 4 hrs. and analyzed engulfment of labeled Aβ by fluorescence intensity. As shown in Fig. 5A, viable platelets are not able to engulf Aβ as seen for THP-1 cells which are known to phagocyte Aβ and served as positive control (Fig. 5A). Furthermore, incubation of platelets with synthetic soluble Aβ led to Aβ-coated platelets that aggregated upon Aβ stimulation (Fig. 5B). Co-staining with the platelet specific marker glycoprotein (GP)Ib confirmed localization of Aβ at the plasma-membrane of platelets using confocal microscopy (Fig. 5B, lower panel).

Activation of apoptotic pathways in platelets can be induced by the pro-apoptotic agent ionomycin or ABT-737 leading to increased intraplatelet Aβ accumulation [33]. Surprisingly, the stimulation of apoptotic pathways in platelets led to the incorporation of pre-aggregated synthetic Aβ comparable to THP-1 cells known to phagocyte Aβ (Fig. 5C). Taken together, vital platelets are not able to engulf Aβ while the stimulation of apoptotic pathways in platelets enables them to engulf pre-aggregated Aβ.

Enhanced Platelet Adhesion upon Aβ Stimulation of Platelets

To elucidate the relevance of Aβ for platelet adhesion under flow conditions, we perfused platelet-rich-plasma (PRP) over the extracellular matrix protein collagen that is exposed upon vessel injury. Pre-treatment of platelets with Aβ led to enhanced platelet adhesion on collagen as seen for intermediate and high blood shear rates [24.14±9.25 cells/visual field versus 142.7±43.22 cells/visual field at a shear rate of 1.000 sec⁻¹, Fig. 6A]. Pre-treatment of platelets with ADP served as positive control. Furthermore, platelet adhesion was observed on immobilized Aβ both under static and dynamic flow conditions (Fig. 6B). High amounts of immobilized Aβ (250 μg/ml) induced platelet adhesion and aggregation (Fig. 6B, upper panel).

In further experiments we perfused whole blood over a mixed collagen/Aβ matrix since accumulation of Aβ in mice results into microbleeds because of vessel injury probably leading to exposure of extra cellular matrix proteins such as collagen. Here we were able to show enhanced accumulation and thrombus formation on a collagen/Aβ surface compared to collagen alone (Figure 6C).

Pre-incubation with Aβ Strongly Enhances Platelet Adhesion at the Injured Carotid Artery of Mice

The above described results indicated that Aβ stimulation of platelets results in platelet activation and induces apoptotic pathways characterized by mitochondrial depolarization, ROS generation, caspase activation and cell membrane scrambling. Furthermore, treatment of platelets with soluble Aβ enhanced platelet adhesion to the extracellular matrix protein collagen. To test the significance of Aβ mediated cellular changes of platelets in platelet accumulation at the injured vessel in vivo, we analyzed platelet adhesion at the injured carotid artery by in vivo fluorescence microscopy. To visualize and quantify platelet adhesion at the ligated carotid artery, platelets from donor mice were fluorescently labeled with DCF. Where indicated, platelets were pre-treated with 50 μg/ml soluble Aβ prior injection into recipient mice. In contrast to control mice without Aβ treatment, platelet adhesion at sites of injury was strongly enhanced when platelets were stimulated with Aβ before injection into mice (Fig. 6D–E,

PLOS ONE | www.plosone.org 5 February 2014 | Volume 9 | Issue 2 | e90523
Figure 3. Aβ stimulation of platelets induces ROS generation and cell membrane scrambling. (A) Generation of ROS from platelets is reported as mean fluorescence intensity (MFI) of DCF. Bar graphs depict mean values ±SEM (n = 5), *p < 0.05 and **p < 0.01. TRAP stimulation of
Platelets and Alzheimer’s Disease

Platelets was used as positive control. (B) Bar graphs depict mean values ± SEM (n = 13) of the percentage of human platelets expressing active caspase-3 following a 60 min exposure to Tyrode buffer (pH 7.4) 2 mM CaCl\textsubscript{2} in the absence and presence of Aβ (1–42) (1–20 ng/ml). *p<0.05 and **p<0.001 indicates statistically significant difference to value in the absence of Aβ. (C) Aβ stimulated platelets were stained for caspase-3 at indicated time points and compared to non-stimulated platelets. (D) Bar graphs depict mean values ± SEM (n = 6) of the cell volume shrinkage in human platelets following a 60 min exposure to Tyrode buffer including 2 mM CaCl\textsubscript{2} in the absence (control) and presence of 1–20 ng/ml Aβ. *p<0.05 indicates statistically significant difference to value in the absence of amyloid. (E) Bar graphs depict mean values ± SEM (n = 7) of Fluo3AM fluorescence in FACS analysis reflecting calcium mobilization of platelets following a 60 min exposure to Tyrode buffer 2 mM CaCl\textsubscript{2} in the absence and presence of Aβ (1–20 ng/ml). *p<0.05 indicates statistically significant difference compared to control. (F) Bar graphs depict mean values ± SEM (n = 5) of DiOC\textsubscript{6} fluorescence in FACS analysis reflecting mitochondrial membrane potential of platelets following a 60 min exposure to Tyrode buffer and presence of Aβ. 0.05 indicates statistically significant difference to value in the absence of Aβ. Ic = isotype control.

Platelets are Recruited to Vascular Amyloid-β Plaques in Brain of APP Dutch and APP23 Transgenic Mice

The use of control platelets and mice showed that treatment with Aβ influences platelet physiology in vitro and in vivo. So far nothing is known about platelets in APP transgenic mice. APP Dutch and APP23 mice are known to develop CAA upon aging where amyloid-β deposits localized mainly to the cerebral vessel walls. Thus we immunohistochemically analyzed brains of APP Dutch and APP23 mice for Aβ deposition and platelet appearance. As shown in Fig. 7A, platelets adhere to vascular amyloid-β plaques in the brain of both, APP Dutch and APP23 mice supporting the hypothesis of active platelet recruitment to amyloid plaques.

In addition, we found that sustained platelet recruitment to vascular amyloid-β deposits can lead to full occlusion of the vessel. This suggests, that contact with Aβ leads to platelet activation and production of Aβ that amplifies platelet activation thus recruiting additional platelets from the blood stream resulting in full occlusion at sites of amyloid-β deposits of cerebral vessels (Fig. 7B).

Taken together, Aβ induces fundamental changes in platelet activation leading to platelet adhesion and aggregation in vitro and in vivo.

Discussion

The present study reveals that contact of platelets with Aβ leads to platelet Aβ production, enhances platelet activation, triggers cell membrane scrambling and shrinkage of platelets, both hallmarks of apoptosis in other cell types. The effects are paralleled by ROS generation, increase of cytosolic Ca\textsuperscript{2+} activity, mitochondrial depolarization and activation of caspase-3. Furthermore we show that platelets modify soluble Aβ leading to an increase in Aβ\textsubscript{42} in the supernatant and extracellular Aβ aggregates/ßllbrids in a dose- and time-dependent manner in platelet cell culture. Whereas vital platelets are not able to absorb synthetic, pre-aggregated Aβ, the induction of platelet apoptosis enables platelets to up-take Aβ as shown for monocytes cells [32]. Interestingly, Aβ stimulation of platelets enhances platelet adhesion under static and dynamic flow conditions ex vivo and at sites of vascular injury in vivo emphasizing our results from histological brain sections showing platelets localized to vascular amyloid-β deposits in cerebral vessel walls of the AD transgenic mice APP Dutch and APP23. The concentrations required to achieve the observed effects are within the range of concentrations observed in vivo. However, it was shown, that plasma Aβ levels fluctuated over time and differ between individuals, suggesting continuous contributions from brain and peripheral tissues and association with reactive circulating proteins [17]. Concentrations of Aβ were reported to approach 150 pg/ml in plasma, 6100 ng/gm in brain grey matter, 1100 ng/gm in brain white matter, 1 ng/ml in minimal atherosclerotic lesion in arteries and 28 ng/gm in leptomeningeval arteries with atherosclerotic plaques [17].

The release of Aβ peptides by circulating platelets was shown by different groups in the past using different platelet agonists. Already in the late nineties, Aβ release from platelets was detected upon stimulation with collagen [34] and thrombin [35]. In contrast we found amounts of released Aβ upon Aβ stimulation that were >10 times higher compared to stimulation with platelet agonists. Surprisingly, treatment with the γ-secretase inhibitor LY411575 revealed that the major amount of Aβ\textsubscript{42} was rather generated by platelet-mediated modification of soluble Aβ\textsubscript{40} than produced by platelets.

Smirnov and colleagues provided evidence that thrombin and prostaglandin 2 regulate the processing and secretion of Aβ peptides and sAPP in human platelets [23]. Here we show for the first time that platelets release Aβ in a dose- and time-dependent manner when they come into contact with soluble exogenous Aβ that is also present in blood under physiological and pathophysiological conditions [17]. Furthermore, we detected Aβ in platelet lysates that may arise from Aβ processed at the plasma membrane of platelets. In contrast we only marginally detected Aβ at the plasma membrane by immunoelectron microscopy. However, there are some limitations of the immunogold technique that makes localization of weak Aβ staining in platelets difficult. Gold particles are around 15–30 nm away from the site to which the primary antibody is bound, thus the precise localization of Aβ cannot be accurately calculated [36]. Furthermore, ultra-thin sections (30 nm) are made for immunogold labelling that can produce misleading results because a thin section of cells may not give an precise view of its three-dimensional structure [36]. In particular, platelets display invaginations of the plasma membrane that can also account for misleading results of localized Aβ. Therefore it seems as if Aβ is also found intracellular and not only at the cell surface.

The fact that Aβ can be released by platelets strengthens the hypothesis that the origin of Aβ in blood might be an additional release of Aβ from blood cells and other non-neuronal cells [37] while others believe that circulating Aβ could derive from the central nervous system through the blood brain barrier [38].

[58x649](n = 5) of DiOC\textsubscript{6} fluorescence in FACS analysis reflecting mitochondrial membrane potential of platelets following a 60 min exposure to Tyrode buffer and presence of Aβ. 0.05 indicates statistically significant difference to value in the absence of Aβ. Ic = isotype control.

doi:10.1371/journal.pone.0090523.g003

video S1 and video S2] suggesting that Aβ influences platelet activation and adhesion at injured vessels in vivo.
Figure 4. Formation of Aβ deposits in human platelet cell culture. Congo red-positive platelets and Aβ deposits in platelet cell culture after stimulation with 50 μg/ml Aβ (A) after 3 days (early state, upper panel) and (B) after 10 days (late state, lower panel). Note the increase in extracellular
The effects of amyloid on platelets apparently involves platelet activation e.g. platelet aggregation as already shown by Shen and colleagues [20,39]. Application of exogenous Aβ (1–2 μM) potentiated platelet aggregation mediated by collagen and other agonists while at higher concentrations (5–10 μM), Aβ induced platelet aggregation without additional stimulus. In contrast to this study we were not able to detect typical parameters of platelet activation such as P-selectin exposure and integrin activation even with high doses of Aβ alone (50 μg, 11.5 μM). Aβ was shown to amplify platelet responses induced by the weak platelet agonist ADP. However, Annexin V positive cells and microparticle formation were already detected upon stimulation with low doses of Aβ demonstrating that variable concentrations of Aβ are needed for different processes of platelet activation.

The generation of reactive oxygen species, defects in mitochondrial function and amyloid metabolism have been already implicated in the pathophysiology of AD in the late nineties [40]. Here we show for the first time that contact of platelets with Aβ induces platelet-mediated ROS production and declines mitochondrial potential that might account for increased ROS levels in brain. Furthermore, the effects of Aβ on platelets apparently involve activation of caspases, as it is significantly blunted in the presence of pancaspase inhibitor zVAD-FMK. The amyloid-induced stimulation of caspase-3 and cell membrane scrambling results at least in part from Ca2⁺ entry, as it is almost abolished by removal of extracellular Ca2⁺. The presence of Ca2⁺ is further a prerequisite for the stimulation of caspase-3 and of cell membrane scrambling. Beside caspase-3 activity and ROS generation, we found other hallmarks of apoptosis and cell membrane scrambling in platelets after contact with Aβ such as cell shrinkage suggesting that Aβ induces apoptosis in platelets. Zaghi and co-workers already provided strong evidence that blood cells such as macrophages undergo apoptosis upon exposure to soluble or fibrillar Aβ [32]. More important macrophage apoptosis alters the ability of these cells to ingest and clear Aβ [32]. This proposes that enhanced Aβ-induced platelet apoptosis also alters blood homeostasis and clearance of platelets from circulating blood as a result of an increase in phosphatidylinerine exposing platelets that are engulfed by phagocytosing cells. Accordingly, excessive platelet apoptosis could thus cause thrombocytopenia. Amyloidosis may indeed be complicated by thrombocytopenia [41].

Beside Aβ-mediated activation and apoptosis of platelets and Aβ release from activated platelets we provided strong evidence for platelet-mediated modulation of soluble Aβ showing that platelets modulate Aβ12/40 ratio as well as soluble exogenously applied synthetic Aβ100 and congo-red positive fibrillar Aβ deposits in a time- and concentration-dependent manner that might contribute to Aβ plaque formation at cerebral vessels detected by immunohistology of brain sections of APP Dutch and APP23 transgenic mice. Experiments using the APP inhibitor LY-411575 confirmed that Aβ aggregates/fibrils in platelet cell culture are not a result of Aβ10/42 release of platelets but may develop from modulation of exogenously applied synthetic Aβ. It is tempting to speculate how platelets are able to achieve modulation of Aβ. Different studies in the past already detected membrane abnormalities in platelets of AD patients [42–44]. A more recent study provided evidence for a modification of membrane properties of platelets from AD patients produced by increased expression and activity of the nitrergic system [45]. If these alterations in membrane properties of platelets in AD patients have any impact in the modulation of soluble Aβ must be analyzed in future experiments. The contradicting results emerged from ELISA measurements of Aβ versus modified Aβ which has been added to the cell culture may be due to the fact that Aβ is only partially modified to fibrillar congo-red positive Aβ while another part is still soluble and thus can be measured by ELISA. However, we do not know the composition of fibrillar Aβ molecules that are produced by platelet-mediated modification in cell culture.

Platelets are not able to engulf Aβ, neither in its soluble nor in a pre-aggregated form as observed for macrophages [32,46]. In contrast, induction of apoptotic pathways in platelets by ABT-737 led to uptake of pre-aggregated Aβ into platelets. A significant increase in intraplatelet Aβ12 was already shown for platelets stimulated with ionomycin [33], leading to the hypothesis that apoptosis of platelets might be related to altered processing of APP [2]. We hypothesize that uptake of Aβ into pro-apoptotic platelets might enhance local accumulation of Aβ when platelets adhere on vascular amyloid plaques at cerebral vessels and undergo apoptosis thereby enhancing cerebral amyloid angiopathy. However, macrophages are known to phagocyte and clear Aβ, processes that were altered in AD patients showing less clearance of Aβ but enhanced apoptosis upon exposure to Aβ. The authors conclude that macrophages shuttle Aβ from neurons to vessels where they undergo apoptosis and subsequently release fibrillar Aβ contributing to CAA [32]. Other proposed mechanisms for the pathogenesis of CAA include Aβ production by myocytes in the vessel wall [47] and more recently Aβ deposition from interstitial fluid being drained from the central nervous system [48].

In this study we provided strong evidence that Aβ activation of platelets initiates a cycle of Aβ release and consequently Aβ mediated platelet activation followed by enhanced platelet adhesion on subendothelial matrix proteins such as collagen under flow conditions as well as at the injured carotid artery as shown here for the first time ex vivo and in vivo. In addition, we show that platelets can adhere to immobilized Aβ under flow to form platelet aggregates, a fact that was further supported by immunohistology studies demonstrating platelet adhesion on Aβ deposits in cerebral vessel walls of AD transgenic mice known to develop CAA. Furthermore, these results are supported by experiments showing that platelets are able to modulate soluble Aβ into fibrillar structures that all might contribute to CAA. More critically continued platelet recruitment to Aβ deposits can lead to full occlusion of the vessel, emphasizing the above described hypothesized cycle of Aβ-mediated activation of platelets that get into contact with Aβ followed by Aβ release that amplifies platelet activation to recruit additional platelets from the blood stream leading to full occlusion of cerebral vessels suggesting microembolization events in AD transgenic mice that might lead to thrombotic events like stroke.

The association of stroke and Alzheimer disease was already suggested for human individuals where the relation is strongest in the presence of vascular risk factors while it remained weakly in the absence of these factors [4]. Results from a case control study of human brain biopsies indicates that CAA is a risk factor for ischemic cerebral infarction [49]. In addition, MRI studies provided evidence that advanced CAA predisposes to ischemic infarction as well as intracerebral haemorrhage [50]. More
Figure 5. Incorporation of synthetic Aβ fibrils by platelets. (A) Viable platelets do not absorb synthetic Aβ fibrils. Different platelet concentrations were incubated with 0.5 μM pre-aggregated FAM-labeled Aβ and fluorescence intensity was measured (upper panel). 10 μM
Cytochalasin D (Cyt D) was used as inhibitor of phagocytosis. THP-1 cells served as positive control. Presence of platelets was controlled by DiOC₆ labeling (100 nM, lower left panel) and by phase contrast microscopy (lower right panel). N = 6; *p<0.05, **p<0.01 and ***p<0.001; n.s. = not significant. (B) Synthetic Aβ was found on the plasma membrane of vital platelets as detected by confocal microscopy. FAM-Aβ (green), platelet specific marker GPIb (red). Scale bar 20 μm. (C) Apoptotic platelets are able to incorporate pre-aggregated FAM-labeled Aβ. Platelets were pre-treated with 1 and 5 μM ABT-737 to induce apoptosis. Fluorescence intensity of FAM-Aβ was measured as indicated. Bar graphs depict mean values ±SEM (n = 6), *p<0.05, **p<0.01. doi:10.1371/journal.pone.0090523.g005

interesting, Schneider and colleagues hypothesized that subcortical infarcts contribute to the destructive effects of Aβ plaque formation in AD pathology by increasing dementia and lowering memory function [51]. However, to date no clear evidence exists that confirmed the correlation of AD and stroke leading to declined cognitive function in APP transgenic mice and patients.

In conclusion, treatment of platelets with Aβ is followed by platelet activation, platelet Aβ release, ROS generation, increase of cytosolic Ca²⁺ activity, mitochondrial depolarization, activation of caspase-3, cell shrinkage and cell membrane scrambling. Furthermore, our results point to a new role for platelets as major caspase-3, cell shrinkage and cell membrane scrambling. Further...

Materials and Methods

Chemicals and Antibodies

Platelets were activated by ADP (Sigma-Aldrich) and soluble Amyloid β (1–40), American Peptide, Cat. No. 62-0-70A, Sequence Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Asp-Ala-Glu-Val-Gly-Ser-Anta-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val. A stock solution with a concentration of 1 mg/ml was prepared using Amyloid β (1–40) solved in sterile Tris buffer and stored at −20°C. Antibodies against APP C-terminal fragment (Covance SIG-39152), amyloid-β (1–16) (Covance, 6E10, SIG-39000) and CN3 [52] were used for immunohistochemistry and immunogold Electron Microscopy. Fluorophore-labeled antibodies anti-P-selectin-FITC (Wug.E9-FITC, Rat IgG2b, Emfret Analytics) and anti-integrin αIIbβ3-PE (JON/A-PE, Rat IgG1, Emfret Analytics) were used for flow cytometric analysis.

Animals

Specific pathogen-free C57BL/6J mice were obtained from Charles River (Sulzfeld, Germany). All animal experiments were conducted according to the Declaration of Helsinki and German law for the welfare of animals. The protocol was approved by the Heinrich Heine University Animal Care Committee and by the district government of North Rhine-Westphalia (LANUV, NRW; Permit Number: 84-02.04.20.12.284, O 86/12, 84-02.04.2012.A405).

Isolation and Stimulation of Human Platelets

Fresh ACD-anticoagulated blood was obtained from healthy volunteers between the age of 22 to 50 years. Participants provided their written informed consent to participate in this study according to the Ethics Committee of the Eberhard Karl University Tuebingen, Germany (184/003 V). To document the process, age and gender were noted. The Ethics Committee of the Eberhard Karl University Tuebingen, Germany approved the consent procedure and specifically this study according to the Declaration of Helsinki. The blood was centrifuged at 200 g for 20 minutes at 25°C without brake. The platelet rich plasma was separated, added with Tyrode buffer (137 mM NaCl, 2.8 mM KCl, 12 mM NaHCO₃, 5 mM glucose, 0.4 mM Na₂HPO₄, 10 mM HEPES, 0.1% BSA), pH 6.5 in a 1:7 volumetric ratio and centrifuged at 900 g and 25°C for 10 minutes with brake. The platelet pellet was resuspended in 500 μl Tyrode buffer pH 7.0.

Murine Platelet Preparation

Platelets were prepared as previously described [33,34]. Briefly, murine blood from retro-orbital plexus was collected and centrifuged at 1800 rpm for 5 minutes at room temperature. To obtain platelet-rich plasma (PRP), the supernatant was centrifuged at 800 rpm for 6 min. PRP was washed twice at 2800 rpm for 5 min at room temperature and pellet was resuspended in Tyrode’s buffer [136 mM NaCl, 0.4 mM Na₂HPO₄, 2.7 mM KCl, 12 mM NaHCO₃, 0.1% glucose, 0.35% bovine serum albumin (BSA), pH 7.4] supplemented with prostacyclin (0.5 μM) and apyrase (0.02 U/mL). Before use, platelets were resuspended in the same buffer and incubated at 37°C for 30 min.

Stimulation of Platelets

Platelets in a concentration of 10⁹/ml were stimulated in Tyrode’s buffer (pH 7.4) containing 2 mM CaCl₂. Where indicated, Aβ was as added at the indicated concentrations (1, 5, 10, 20, 50 ng/ml and 50 μg/ml) for 60 minutes at 37°C. A negative control without amyloid and a positive control with thrombin 0.1 U/ml were analyzed simultaneously with each set of experiment.

Human and Murine Platelet Culture

Human or murine platelets were prepared as described and adjusted to a final concentration of 2×10⁷ platelets per 150 μl medium (DMEM). Platelets were stimulated with 50 ng or 50 μg Aβ for indicated time points. After incubation, unbound platelets were removed by rinsing with Tyrode’s buffer while adherent platelets were fixed with 4% paraformaldehyde and stained for Aβ, caspase-3 and P-selectin, respectively. Samples were analyzed by confocal microscopy and at least 8 confocal images were taken for each sample. For the analysis of amyloid-β plaque formation, Congo red-positive Aβ deposits in platelet cell culture were determined at different time points. Where indicated, platelets were pre-treated with the γ-secretase inhibitor LY 411575 (0.1 μM). Analysis was performed using a 63x objective and a Zeiss Axioskop 2 microscope (Zeiss).

Amyloid β Quantification by Enzyme Linked Immunosorbent Assay (ELISA)

Platelets were adjusted to a final concentration of 2×10⁷ in a volume of 150 μl and stimulated with Amyloid β as indicated. Accumulation and release of Aβ into the platelet cell supernatant was measured for the indicated time points following the manufacturer’s protocol (Aβ 42 Human ELISA Kit, Invitrogen). Where indicated, platelets were pre-treated with the γ-secretase inhibitor LY 411575 (0.1 μM).
Flow Cytometry

Flow cytometry analysis was performed as described elsewhere [55]. Briefly, two-colour analysis of murine platelet activation was performed using fluorophore-labeled antibodies for P-selectin expression (Wug.E9-FITC) and the active form of \( \alpha_{IIb} \beta_3 \) integrin (JON/A-PE). Heparinized blood was diluted in Tyrode buffer and washed twice. Blood samples were mixed with antibodies after addition of 1 mM CaCl\(_2\) and stimulated with indicated agonists for 15 min at room temperature. Reaction was stopped by the addition of PBS and samples were analyzed on a FACSCalibur flow cytometer (BD Biosciences).

Transmission Electron Microscopy (TEM)

Resting or activated platelets were incubated with A\( \beta \) in medium for 24 hrs and controlled by phase contrast microscopy. Subsequently, the cells were fixed in Karnovsky’s solution for 1 h at room temperature and stored at 4°C. For electron microscopic studies, cell pellets were embedded in agarose at 37°C, coagulated, cut in small blocks, fixed in Karnovsky’s solutions, postfixed in osmium tetroxide, and embedded in glycid ether and cut using an ultramicrotome (Ultracut Reichert, Vienna, Austria). Ultrathin sections (30 nm) were mounted on copper grids and analyzed using a Zeiss LIBRA 120 transmission electron microscope (Carl Zeiss, Oberkochen, Germany) [56–58].

Immunogold Electron Microscopy (IEM)

For IEM of A\( \beta \) and the precursor APP, platelets were fixed in glutaraldehyde (0.01%) and paraformaldehyde (3%) and embedded in 3% agarose. Small parts of the agarose blocks were embedded in Lowicryl (Polysciences Ltd.). 30-nm ultra-thin sections were mounted on copper grids and analyzed using a Zeiss LIBRA 120 transmission electron microscope (Carl Zeiss, Oberkochen, Germany) [56–58].

Phagocytosis Assay

For the analysis of the phagocytosis potential of platelets, synthetic A\( \beta \) was prepared as follows: FAM-labeled A\( \beta \) (Anaspec, Beta-Amyloid (1–42)-Lys(Biotin), FAM–labeled, Sequence: FAM–Asp-Ala-Glu-Phe-Arg-His-Asp-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-Lys(Biotin)-OH) was dissolved at equimolar concentrations in PBS to reach a
final concentration of 15 μM total Aβ. To generate fibrils, the peptide was incubated for 3 days at 37°C and subsequently stored at −20°C. Platelets (1×10⁶) were seeded in a volume of 150 μl medium in 96 well plates. FAM-labeled synthetic Aβ preparation was added and incubated for 4 hrs. under normal growth conditions. Medium was aspirated and 100 μl trypan blue solution was added to quench extracellular fluorescence. After removing trypan blue, intracellular fluorescence was measured at 485 nm (excitation) and 535 nm (emission). To control the presence of cells, platelets were labeled with 100 nM DIOC6 and additionally monitored by phase contrast microscopy.

Phosphatidylserine Exposure
Phosphatidylserine exposure resulting from cell membrane scrambling was measured after stimulation with Aβ, followed by centrifugation of cells at 1000 g for 2 minutes and incubation with 1:20 dilution of Annexin V Fluos (Immunotools, Germany) in Tyrode buffer (pH 7.4) supplemented with 2 mM CaCl₂ for 30 minutes in the dark at room temperature. The forward scatter was determined and the fluorescence was measured in FL-1 of a BD FACSCalibur (BD Biosciences, CA, USA).

Cell Volume and Microparticle Release
Isolated platelets were resuspended at a concentration of 10⁶/ml of Tyrode buffer (pH 7.4) with 2 mM CaCl₂ and stimulated with designated concentrations of Aβ (1–20 ng/ml) for 60 minutes at 37°C and washed once in Tyrode buffer (pH 7.4). Washed platelets were stained with GPIb (CD42b PE, BD Biosciences) for 30 minutes at room temperature in the dark and analyzed in the FSC vs. SSC plot with FSC (E00) settings in the Log scale for cell volume (FCS Geomena) and E01 for detection of microparticles [61].

Cytosolic Calcium
Intracellular Ca²⁺ concentration was measured following stimulation with Aβ as indicated, washing once in Tyrode buffer (pH 7.4) with 2 mM CaCl₂, staining with 5 μM Fluo-3AM (Biotium, USA) in the same buffer and incubating at 37°C for 30 minutes. The fluorescence was measured in FL-1 of a BD FACSCalibur (BD Biosciences, CA, USA).

Caspase-3 Activity
For determination of caspase-3 activity, 10⁶ platelets/ml were suspended in Tyrode buffer (pH 7.4) with 2 mM CaCl₂ and stimulated with 1, 5, 10 and 15 ng/ml concentrations of amyloid. Caspase-3 activity was measured by CaspGlow Fluorescein Active

Figure 7. Recruitment of platelets to vascular amyloid-β deposits in brain of APP Dutch and APP23 transgenic mice. (A) Platelet adhesion to vascular Aβ plaques in cerebral vessels of both, APP23 (upper, middle panel) and APP Dutch (upper, right panel) transgenic mice was analyzed by confocal microscopy. Brains were immunohistochemically analyzed for Aβ deposition (6E10, red) and the presence of platelets using the platelet specific marker GPIb (green). (B) Sustained platelet recruitment to vascular amyloid-β deposits leads to full occlusion of the vessel (lower panel). Overlay of Aβ immunoreactivity (red) and GPIb (green) is shown in yellow (merge), staining of cell nuclei (blue), scale bar 20 μm. doi:10.1371/journal.pone.0090523.g007
Mitochondrial Membrane Potential
In order to measure the depolarization of the outer membrane of platelet mitochondria, 10^7 platelet/ml of Tyrode buffer (pH 7.4) with 2 mM CaCl₂ were first stimulated with Aβ as described before. Then platelets were centrifuged and resuspended in phosphate buffered saline (PBS) (Invitrogen, CA, USA) supplemented with 1 mM MgCl₂, 5.6 mM glucose, 0.1% BSA and 10 mM HEPES (pH 7.4) in a total volume of 1 ml and stained with 10 nM DiOC₆ (Invitrogen, CA, USA) for 10 minutes. The stained cells were centrifuged at 1000 g for 2 minutes at 25°C, resuspended in PBS and measured by flow cytometry [62].

Free Radical Generation (ROS) from Platelets in Response to Aβ
The intracellular ROS generation of cells can be investigated using the 2',7'-dichlorofluorescein-diacetate (DCFH-DA). Platelets (2×10⁶/ml) were incubated in the presence of unlabeled Aβ (50 ng/ml and 50 µg/ml) for 24 hrs. Following which platelets were treated with DCFH-DA (10 nM and 50 µg/ml) for 24 hrs. Following which platelets were centrifuged and resuspended in 1 mM MgCl₂, 5.6 mM glucose, 0.1% BSA and 10 mM HEPES (pH 7.4) in a total volume of 1 ml and stained with 10 nM DiOC₆ (Invitrogen, CA, USA) for 10 minutes. The stained cells were centrifuged at 1000 g for 2 minutes at 25°C, resuspended in PBS and measured by flow cytometry [62].

Platelet Adhesion under Flow using the Flow Chamber
Cover slips (24×60 mm) were coated with 200 µg/ml fibrillar type I collagen (Nycodenz) or human fibrinogen (1 mg/ml) overnight and then blocked with 300 µl of 1% BSA solution for at least 60 min. Tyrode’s buffer was prepared as described before. PH was adjusted to 7.4 and the Tyrode’s buffer was prewarmed at room temperature. Resting platelets were treated with platelet agonist TRAP (25 µM) in the presence of DCFH-DA and mouse anti-human CD42b-PE (Beckman Coulter) antibody for 30 minutes at room temperature. Resting platelets were treated with platelet agonist TRAP (25 µM) in the presence of DCFH-DA and mouse anti-human CD42b-PE to compare ROS generation among Aβ treated and agonist activated platelets with respect to non-activated resting platelets. At the end of the incubation period samples were analyzed by flow cytometry (FACS Calibur, Becton Dickinson) gating for the platelet specific CD42b positive population. Fluorescence of 10,000 cells was acquired and analyzed by the Cell Quest program to determine the mean fluorescence. Generation of ROS from platelets is reported as mean fluorescence intensity of DCF [63].

Platelet Adhesion on Immobilized Amyloid β
Synthetic Aβ (50 and 250 µg/ml) was immobilized on cover slips (24×60 mm) overnight and then blocked with 300 µl of 1% BSA solution for at least 60 min. PRP was prepared as described and platelet count was adjusted to 2×10⁹ platelets/ml. Platelet adhesion and aggregate formation was analyzed under static and flow condition. In additional experiments, whole blood was perfused over a collagen/Aβ matrix and thrombus formation was analyzed by surface coverage. Carotid Ligation in Mice and Assessment of Platelet Adhesion by Intravital Microscopy
To evaluate the effect of Aβ on platelet activation and adhesion in vivo, we used intravital fluorescence microscopy. Prior to the experiments, platelets from donor mice were stained with 5-carboxyfluorescein diacetate succinimidyl ester (DCF) and incubated with 50 µg/ml soluble Aβ for 30 min. Wild-type C57BL/6J mice (Charles River Laboratories) were anesthetized with medetomidine, midazolam and fentanyl. Polyethylene catheters (Portex) were implanted into the right jugular vein, and fluorescent platelets (8×10⁶/150 µl) were injected intravenously [53,55,64]. The common carotid artery was dissected free and ligated vigorously for 5 min to induce vascular injury. Before and after vascular injury, interaction of the fluorescent platelets with the injured vessel wall was visualized by in vivo video microscopy of the common carotid artery using a Leica microscope (20×water immersion objective, W 20×/0.5; Leica DM2500MH) [53,55,64].

Histology and Immunohistochemistry
Brains were removed and immersion fixed for 48 hrs in paraformaldehyde (4%), then cryoprotected in 30% sucrose for additional 2 days [1]. After freezing, serial 25-µm thick coronal sections were cut through the brains using a freezing-sliding microtome. The sections were collected in 0.1 M Tris-buffered saline and stained immunohistochemically. Polyclonal antibody CN3 [52] was used for immunostaining of Aβ and monoclonal antibody CD42b was used for immunostaining of the platelet specific glycoprotein Ib (GPIb) (US Biological).

Statistical Analysis
Data are provided as arithmetic means ± SEM (standard error of mean), statistical analysis was made by one-way ANOVA or student’s paired t-test, where applicable.

Supporting Information
Figure S1 Accumulation of Aβ(1–42) measured by a sandwich ELISA assay. Aβ(1–42) levels measured in different control experiments: Medium alone, supernatant of resting platelets and medium supplemented with 50 ng/ml Aβ(1–40) and 50 µg/ml Aβ(1–40), respectively. Bar graphs depict mean values ± SEM (n = 4–8) of Aβ1–42 levels as indicated. (PDF)

Figure S2 Formation of Aβ deposits in murine platelet cell culture. Congo red-positive platelets and Aβ deposits in platelet cell culture of C57BL/6J mice after stimulation with 50 µg/ml Aβ in the presence and absence of the APP inhibitor LY-411575 after 10 days in culture. (right panel). Approaches with medium and Aβ or platelets alone served as controls to confirm that Aβ does not pre-aggregate to produce congo red-positive Aβ deposits spontaneously. Scale bar 20 µm. (PDF)

Figure S3 Platelet-mediated modulation of soluble Aβ into congo red-positive fibrils is concentration-dependent. Congo red-positive platelets and Aβ deposits in platelet cell culture after stimulation with indicated concentrations of soluble Aβ after 10 days. Note the increase in extracellular Aβ deposits with Aβ concentrations >1 µM. Scale bar 20 µm. (PDF)

Video S1 Video of in vivo platelet adhesion at the injured carotid artery. Platelet adhesion to the ligated carotid
artery was analyzed by intravital fluorescence microscopy using platelets from donor mice without any (pre-) treatment (control mouse). Platelets were labeled with DCF for visualization and quantification. AVI)

Video S2 Video of in vivo platelet adhesion at the injured carotid artery after pre-treatment with Aβ. Video S2 shows enhanced platelet adhesion to sites of injury after pre-treatment of donor platelets with Aβ prior injection into recipient mouse. Platelets are labeled with DCF for visualization and quantification. AVI)

References

1. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, et al. (2011) Soluble Aβeta seeds are potent inducers of cerebral beta-amyloid deposition. J Neurosci 31: 14480–14495.

2. Matteoni A, Torni M, Ricciuti G (2012) Alzheimer disease and platelets: how’s it relevant. Immun Ageing 9: 20.

3. Thal DR, Griffin WS, de Vos RA, Ghrebelmedhi E (2006) Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease. Acta Neuropathol 115: 59–69.

4. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, et al. (2003) Stroke and the risk of Alzheimer disease. Arch Neurol 60: 1707–1712.

5. Mielke MM, Rosenberg PB, Tschanz J, Corcoran C, et al. (2007) Vascular factors predict rate of progression in Alzheimer disease. Neurology 69: 1585–1588.

6. Luchsinger JA, Reitz C, Honig LS, Shea S, et al. (2005) Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65: 545–551.

7. Iadecola C. (2004) Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat Rev Neurosci 5: 547–560.

8. Staffen W, Berghoff A, Scholz C, Wunderlich M, et al. (2009) Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer’s type: a semi-quantitative and automated evaluation. Eur J Nucl Med Mol Imaging 36: 801–810.

9. Hardy J (2007) Does Abeta 42 have a function related to blood homeostasis? Neurochem Res 32: 833–835.

10. Smith EE, Greenberg SM, et al. (2009) Beta-amyloid, blood vessels, and brain function. Stroke 40: 2601–2606.

11. Gawaz M, Langer H, May AE. (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115: 3378–3384.

12. Kroll MH, Schafer AI (1989) Biochemical mechanisms of platelet activation. Blood 74: 1181–1195.

13. Racchi M, Govoni S (2003) The pharmacology of amyloid precursor protein kinase C pathway in platelet activation. Pharmacol Res 57: 151–158.

14. Casoli T, Di Stefano G, Giorgi G, Grossi Y, Balietti M, et al. (2007) Release of amyloid beta-precursor protein of Alzheimer’s disease by normal human platelets. J Biol Chem 282: 19097–19105.

15. Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 213: 96–103.

16. Deane R, Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 4: 191–197.

17. Roher AE, Ehl CL, Kohjoh TA, Castano EM, Van Vickle GD, et al. (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement 5: 18–29.

18. Kitaguchi N, Takahashi Y, Tokushima Y, Shiojiri S, Ito H (1988) Novel protein kinase C inhibitor is a selective platelet activator. Biochem Biophys Res Commun 155: 1552–1562.

19. Wolf BB, Goldstein JC, Steunucke HR, Beere H, Araznante-Mendez GP, et al. (1999) Calcium functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 94: 1683–1692.

20. Zheng J, Goldenson B, Inayathullah M, Losinsky AS, Masoumi A, et al. (2009) Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol 117: 111–124.

21. Casoli T, Di Stefano G, Giorgi G, Grossi Y, Balietti M, et al. (2007) Release of beta-amyloid from high-density platelets: implications for Alzheimer’s disease pathology. Ann N Y Acad Sci 1096: 170–178.

22. Smich CC (1997) Stimulated release of the beta-amyloid protein of Alzheimer’s disease by normal human platelets. Neurosci Lett 235: 157–159.

23. Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, et al. (1998) Secretion of Alzheimer’s disease Abeta amyloid peptide by activated human platelets. Lab Invest 78: 461–469.

24. Hermann R, Walther P, Muller M (1996) Immunogold labeling in scanning electron microscopy. Histochem Cell Biol 106: 31–39.

25. Davies TA, Long HJ, Eisenhauer PB, Hasery R, Cribbs DH, et al. (2007) Beta-amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood barrier endothelial cell model system. Amyloid 7: 153–165.

26. Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GI (2006) Coated-platelets retain amyloid precursor protein on their surface. Platelets 17: 56–60.

27. Shem MY, Hsiao G, Tong TH, Chen HM, Choi DS, et al. (2008) Amyloid beta peptide-activated signal pathways in human platelets. Eur J Pharmacol 588: 259–266.

28. Sherhan JP, Sweenrow RH, Miller SW, Davis RE, Parks JK, et al. (1997) Calcium homeostasis and reactive oxygen species production in cells transformed by mitochonidia from individuals with sporadic Alzheimer’s disease. J Neurosci 17: 4612–4622.

29. Eder L, Bitterman H (2007) Image in clinical medicine. Amyloid purpurea. N Engl J Med 356: 2406.

30. Cohen BM, Zuberko GS, Babb SM (1987) Abnormal platelet membrane composition in Alzheimer’s-type dementia. Life Sci 40: 2461–2465.

31. Piletz JE, Sarasu M, Whitehouse P, Chotani M (1991) Intracellular membranes are more fluid in platelets of Alzheimer’s disease patients. Neurobiol Aging 12: 459–466.

32. Zuberko GS, Cohen BM, Beller F, Malinakova I, Keele N, et al. (1987) Platelet membrane abnormalities in Alzheimer’s disease. Ann Neurol 22: 237–244.

33. Vignini A, Nanetti L, Moroni C, Tanase L, Bartolini M, et al. (2007) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Curr Alzheimer Res 4: 191–197.

34. Smith CC (1997) Stimulated release of the beta-amyloid protein of Alzheimer’s disease by normal human platelets. Neurosci Lett 235: 157–159.

35. Smich CC (1997) Stimulated release of the beta-amyloid protein of Alzheimer’s disease by normal human platelets. Neurosci Lett 235: 157–159.

36. Hermann R, Walther P, Muller M (1996) Immunogold labeling in scanning electron microscopy. Histochem Cell Biol 106: 31–39.

37. Davies TA, Long HJ, Eisenhauer PB, Haste R, Cribbs DH, et al. (2007) Beta-amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood barrier endothelial cell model system. Amyloid 7: 153–165.

38. Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GI (2006) Coated-platelets retain amyloid precursor protein on their surface. Platelets 17: 56–60.

39. Shem MY, Hsiao G, Tong TH, Chen HM, Choi DS, et al. (2008) Amyloid beta peptide-activated signal pathways in human platelets. Eur J Pharmacol 588: 259–266.

40. Sherhan JP, Sweenrow RH, Miller SW, Davis RE, Parks JK, et al. (1997) Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer’s disease. J Neurosci 17: 4612–4622.

41. Eder L, Bitterman H (2007) Image in clinical medicine. Amyloid purpurea. N Engl J Med 356: 2406.

42. Cohen BM, Zuberko GS, Babb SM (1987) Abnormal platelet membrane composition in Alzheimer’s-type dementia. Life Sci 40: 2461–2465.

43. Piletz JE, Sarasu M, Whitehouse P, Chotani M (1991) Intracellular membranes are more fluid in platelets of Alzheimer’s disease patients. Neurobiol Aging 12: 459–466.

44. Zuberko GS, Cohen BM, Beller F, Malinakova I, Keele N, et al. (1987) Platelet membrane abnormalities in Alzheimer’s disease. Ann Neurol 22: 237–244.

45. Vignini A, Nanetti L, Moroni C, Tanase L, Bartolini M, et al. (2007) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Curr Alzheimer Res 4: 191–197.

Acknowledgments

We thank Birgit Feuerhacker, Jadwiga Kwiatowska and Martina Spelleken for providing outstanding technical assistance and Christoph Klett for preparing the figures. We are indebted to Dr. Kordt for critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: ME. Performed the experiments: NSG LD MC YSE STT PM BW IO OB M. Grandoch ME. Analyzed the data: MS JWF M. Gawaz SW FL MJ ME. Wrote the paper: ME.
47. Wisniewski HM, Frackowiak J, Mazur-Kolecka B (1995) In vitro production of beta-amyloid in smooth muscle cells isolated from amyloid angiopathy-affected vessels. Neurosci Lett 183: 120–123.

48. Weller RO, Nicoll JA (2003) Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res 25: 611–616.

49. Cadavid D, Meno H, Koeller K, Frommelt RA (2000) Cerebral beta amyloid angiopathy is a risk factor for cerebral ischemic infarction. A case control study in human brain biopsies. J Neuropathol Exp Neurol 59: 768–773.

50. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, et al. (2009) Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 72: 1230–1235.

51. Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA (2007) Subcortical infarcts, Alzheimer’s disease pathology, and memory function in older persons. Ann Neurol 62: 59–66.

52. Elvers M, Pozgaj R, Pleines I, May F, Kuijpers MJ, et al. (2010) Platelet hyperreactivity and a prothrombotic phenotype in mice with a gain-of-function mutation in phospholipase C-gamma2. J Thromb Haemost 8: 1353–1363.

53. Pleines I, Elvers M, Strehl A, Pozgajova M, Varga-Szabo D, et al. (2009) Rac1 is essential for phospholipase C-gamma2 activation in platelets. Pflugers Arch 457: 1173–1183.

54. Langer HF, von der Ruhr JW, Daub K, Schoenenberger T, Stellos K, et al. (2010) Capture of endothelial progenitor cells by a bispecific protein/cadherin antibody molecule induces reendothelialization of vascular lesions. J Mol Med (Berl) 88: 667–699.

55. Elvers M, Pozgaj R, Pleines I, May F, Kuijpers MJ, et al. (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330: 980–982.

56. Leytin V, Allen DJ, Mykhaylov S, Lyubimov E, Freedman J (2006) Thrombin-triggered platelet apoptosis. J Thromb Haemost 4: 2656–2663.

57. Chatterjee M, Sahaja R, Kumar V, Jyoti A, Kumar Jain G, et al. (2008) Ascorbate sustains neutrophil NOS expression, catalysis, and oxidative burst. Free Radic Biol Med 45: 1084–1093.

58. Massberg S, Brand K, Gruner S, Page S, Muller E, et al. (2002) A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196: 487–496.